The characterization of over 300 mutants, derived from two strains of poliovirus type 3 and selected for resistance to neutralization by monoclonal antibodies, has led to the further definition of the major antigenic site involved in neutralization. The site encompasses amino acids 89 to 100 of VP1. A subsidiary antigenic site near the Cterminus of VP1 has been identified for the Sabin vaccine strain of poliovirus type 3. Of 59 monoclonal antibodies to poliovirus type 3 examined, 27 had virus-neutralizing activity and 25 of these were identified as directed against the major site on VP1 (designated site 1), indicating the immunodominant role of this site. One of the six monoclonal antibodies that recognized the subsidiary antigenic site on VP1 (designated site 2) possessed virus-neutralizing activity. The identification of the principal antigenic site of the virus provides a rational basis for attempts at the development of synthetic oligopeptide vaccines against poliovirus type 3.
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Polioviruses can be divided into three serotypes on the basis of their neutralization reactions with specific immune sera. However, they have similar virological properties and clinical effects and the nucleic acid and amino acid sequences of all three serotypes are strikingly similar (Stanway et al., 1983 (Stanway et al., , 1984 .
We have previously reported the location of a single, major antigenic site involved in the neutralization of poliovirus type 3, 93 to 100 amino acids from the N-terminus of VP1 (Minor et al.~ 1983 : Evans et al., 1983 ). This conclusion was based on the isolation of mutant polioviruses resistant to neutralization by monoclonal antibodies which had amino acid substitutions clustered in this region. In contrast to these findings, Emini et al. (1983) have concluded that neutralization of poliovirus type 1 involves multiple epitopes, some of which appeared to he independent, and thus involve independent antigenic sites. If correct, this difference between closely related viruses would make the satisfactory prediction of viral peptide sequences for use as novel vaccines (Shinnick et al., 1983) more difficult than hitherto supposed. We have therefore extended our studies to define more precisely the antigenic structures involved in the neutralization of type 3 poliovirus by monoclonal antibodies.
The work reported here enabled further definition of the main antigenic site of the wild, virulent P3/Leon/USA/1937 (P3/Leon/37) strain of poliovirus type 3, and has shown that the corresponding site is involved in the neutralization of the attenuated Sabin poliovirus type 3 vaccine virus (P3/Leon 12alb). It has also led to the conclusion that the great majority of monoclonal antibodies with neutralizing activity recognize this site. We also report the location of a second, minor antigenic site in the Sabin type 3 vaccine virus, located near the C-terminus of VP1.
Mutants resistant to neutralization by specific monoclonal antibodies were isolated from plaques formed by antibody-treated virus under an agar overlay containing antibody (Minor et al., 1983) . They were isolated from the type 3 poliovirus strain P3/Leon/37 (Minor et at., 1983; Evans et al., 1983) and its attenuated derivative, the Sabin vaccine strain. The mutants were 0000-6395 © 1985 SGM 
* Mutant viruses were said to be sensitive to antibody if a 1 : 10 dilution of antibody as ascitic fluid was able to preserve a cell sheet from challenge with 10 ~ TCIDs0 of virus during incubation at 35°C for 2 days. Results were checked by plaque assay in the presence of dilutions of antibody (Minor et al., 1983 : Evans et al., 1983 . t r indicates resistance.
characterized by their susceptibility to neutralization by a panel of 12 monoclonal antibodies as shown in Table 1 . Mutants obtained from a total of 213 plaques derived from P3/Leon/37 virus could be classified into 16 distinct groups on the basis of the pattern of their neutralization. Similarly, 15 distinct groups of the Sabin vaccine strain were selected from a total of 129 plaques.
Mutants of each group were examined by primer extension sequencing of their RNAs. Representatives of each of the 16 groups of mutants derived from P3/Leon/37 possessed a single amino acid substitution in VP1 in the sequence from residues 91 to 100 inclusive (Table 2 ). An amino acid substitution was found in position 91 (Asp-Ala) for one of the groups for which we had previously been unable to locate a mutation (Evans et al., 1983) . Twelve of the 15 groups of mutants derived from the Sabin vaccine virus were found to possess single amino acid substitutions located at residues from 89 to 100. Two groups of mutants, I and Q, had no amino acid substitutions at positions 89 to 100, but amino acids at positions 253 and 166 respectively were substituted. No amino acid substitution in VP 1 was identified for group L. There was some evidence that the mutants of this group were unstable and reverted to wild-type as the growth of virus pools grown from this mutant, like that of the wild-type, was retarded by all antibodies.
Virus later broke through in the appropriate incubations indicated in Table 1 , however. The virus seed did not show this behaviour, growing freely in the presence of antibodies 199, 194, 
